Cytosorbents Corporation (CTSO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Cytosorbents Corporation (CTSO) is down 43.5% since the beginning of the year. At $0 per share, CTSO is trading 70.4% below its 52-week high of $1. Investors who bought $1,000 worth of CTSO shares 5 years ago would now be looking at an investment worth $47.

Cytosorbents Corporation (CTSO) has returned -43.54% so far this year and -58.48% over the past 12 months. Over the last ten years, CTSO has returned -22.62% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.

Based on dividend-adjusted daily data since Nov 7, 2013, CTSO's average daily return is +0.05%, while the average monthly return is +0.92%. At this rate, an investment would double in approximately 6.3 years.

Historically, 45% of months were positive and 55% were negative. The best month was Jan 2014 with a return of +124.0%, while the worst month was Apr 2015 at -46.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 10 months.

On a daily basis, CTSO closed higher 46% of trading days. The best single day was Jan 22, 2014 with a return of +67.6%, while the worst single day was Dec 28, 2023 at -33.4%.

Cytosorbents Corporation has an annualized alpha of 1.23%, beta of 0.82, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since November 07, 2013.

• This stock participated in 127.51% of S&P 500 Index downside but only 9.63% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CTSO ranks 12 for risk / return — above 12% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Cytosorbents Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Cytosorbents Corporation was 97.66%, occurring on Jul 30, 2026. The portfolio has not yet recovered.

The current Cytosorbents Corporation drawdown is 97.59%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Cytosorbents Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Cytosorbents Corporation is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.